Improving HER2 testing reproducibility in HER2-low breast cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

31 citing papers in PubMed.

1. Clinicopathological Features and Prognostic Impact of Human Epidermal Growth Factor Receptor 2-Low Status in Early-Stage Breast Cancer: A Single-Center Cohort Hormone Receptor-Stratified Retrospective Analysis.Cureus · 2026
   Article
2. Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia.Asia-Pacific journal of clinical oncology · 2026
   Review
3. Digital image analysis improves diagnostic accuracy of HER2-low and HER2-ultralow breast cancer: a step towards personalised medicine.Virchows Archiv : an international journal of pathology · 2026
   Article
4. Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.World journal of oncology · 2026
   Review
5. AI-enhanced precision: boosting pathologist confidence in HER2 ultra-low diagnosis through intelligent re-screening.Breast cancer research : BCR · 2026
   Article
6. Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-Null to HER2-low, including HER2-ultralow status.Virchows Archiv : an international journal of pathology · 2026
   Article
7. Dynamics of HER2 status following neoadjuvant systemic therapy in breast cancer: a large single-center cohort analysis.Therapeutic advances in medical oncology · 2026
   Article
8. Standardizing the pathologic assessment of HER2-(ultra)low breast cancer: insights from a national Italian project.Pathologica · 2025
   Article
9. Immunohistochemistry for PTEN testing in HR +/HER2- metastatic breast cancer.Virchows Archiv : an international journal of pathology · 2025
   Review
10. Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement.The Indian journal of medical research · 2025
    Review
11. Dual-targeting and steric hindrance resolution in HER2 IHC: a novel approach to improve diagnostic sensitivity.BMC cancer · 2025
    Article
12. Effect of HER2-low status on brain metastasis-free survival and survival after brain metastasis in patients with breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
13. The "lows": Update on ER-low and HER2-low breast cancer.Breast (Edinburgh, Scotland) · 2024
    Review
14. Computational pathology in the identification of HER2-low breast cancer: Opportunities and challenges.Journal of pathology informatics · 2024
    Review
15. The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer.BMC cancer · 2024
    Article
16. The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.Scientific reports · 2024
    Article
17. Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer.Diagnostic pathology · 2024
    Article
18. Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence.Cancers · 2024
    Review
19. A gene expression-based classifier for HER2-low breast cancer.Scientific reports · 2024
    Article
20. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers.International journal of molecular sciences · 2024
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as